Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Dragon III- Phase 2: The Preliminary Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: Open-label, Randomized Controlled Trial
Sponsor: Ruijin Hospital
Listed as NCT03636893, this PHASE2 trial focuses on Chemotherapy Effect and Gastric Cancer and remains completed. Sponsored by Ruijin Hospital, it has been updated 11 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Completed PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed · Phase: None → PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting · Phase: PHASE2 → None
-
Sep 2018 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .